Objectives: The aim was to identify metabolic subtypes within metabolically unhealthy obesity (MUO) using integrated metabolomics and hematology data and evaluate their differential risks for cardiovascular–kidney–metabolic (CKM)-related outcomes. Methods: Among 62,341 obese UK Biobank participants (43,577 MUO; 18,764 non-MUO), least absolute shrinkage and selection operator regression selected 67 biomarkers from 96 metabolites and serological parameters, followed by K-means clustering. Cox proportional hazards models assessed subtype-specific associations with incident CKM-related outcomes over a median 14.81-year follow-up. Results: Four metabolic subtypes were identified within MUO, characterized by distinct amino acid, renal, and lipid profiles. Subtype-specific associations with CKM-related outcomes differed substantially. Compared with non-MUO participants, Subtype II and Subtype IV were associated with higher coronary heart disease risk (HR, 1.34; 95% CI, 1.11–1.61 and HR, 1.37; 95% CI, 1.15–1.64, respectively), Subtype IV was associated with lower atrial fibrillation risk (HR, 0.73; 95% CI, 0.60–0.90), Subtype III with higher heart failure risk (HR, 1.42; 95% CI, 1.10–1.82), and Subtype I with higher chronic kidney disease risk (HR, 1.52; 95% CI, 1.22–1.91). Conclusions: Integrated metabolomic and hematologic profiling identified variation in the metabolic profiles of individuals with MUO. The four subtypes showed different patterns of association with CKM-related outcomes, suggesting that MUO encompasses diverse metabolic profiles that may not be fully captured by conventional metabolic syndrome criteria.
No takes yet. Share an insight, caveat, or question.
Huang et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: